Research Article

Do Anti-Vimentin Antibodies Play a Role in Psoriasis?

Author: Agnieszka Owczarczyk-Saczonek

Antibodies against Citrullinated Proteins/Peptides (ACPAs), and especially antibodies targeting citrullinated vimentin (anti-Sa), are novel biomarkers of Rheumatoid Arthritis (RA) and also in Psoriatic Arthritis (PsA). The aim of the present study was to investigate the prevalence of anti-Sa in 54 PsA and PsO patients aged 20-69 years (22 F and 32 M). Each patient was assessed with Psoriasis Area and Severity Index - PASI score (severity of psoriasis), the presence of antibodies against vimentin (anti-Sa) and Antinuclear Antibodies (ANA) on HEp- 2 cells. There were no statistically significant differences between the mean values of the PASI and the presence of antibodies to vimentin or the antinuclear antibodies. Additionally analysis showed that the incidence of antibodies against vimentin (anti-Sa) in patients with plaque psoriasis was similar for patients with also psoriatic arthritis (65.115% vs. 62.5%). On the other hand, it can be concluded that the presence of them is much more common in patients with psoriasis than healthy controls - the highly significant statistical differences (p = 0.003). Our results suggest that the presence of anti-Sa in psoriasis confirm the autoimmune nature of this disease